May 22nd 2025
Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.
Watch the series now!
Jennifer Malin, MD, Explains Payer Role In Changing Cancer Care
Colorectal Cancer Screening Gets Special Look in AJMC Papers